G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/574 (2006.01) C12Q 1/68 (2006.01)
Patent
CA 2707729
Provided herein are the biomarkers for monitoring the treatment by quinazolinone compounds. For example, the use of SPARC, p21, and cyclin D1 mRNA levels as biomarkers to predict whether a quinazolinone compound is likely to be successful in treating certain types of cancer, such as NHL is provided. Further, the expression of these genes can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with quinazolinone compounds.
La présente invention concerne des biomarqueurs pour suivre le traitement par des composés quinazolinone. Par exemple, l'invention concerne l'utilisation des niveaux d'ARNm du SPARC, du p21, et de la cycline D1 comme biomarqueurs pour prédire si un composé quinazolinone est susceptible de donner des résultats dans le traitement de certains types de cancer, tels que le lymphome malin non hodgkinien (NHL). En outre, l'expression de ces gènes peut être utilisée pour suivre le progrès de l'efficacité du traitement et de la complaisance du patient chez des patients du cancer qui reçoivent un traitement par des composés quinazolinone.
Bartlett J. Blake.
Schafer Peter H.
Zhang Ling-Hua
Celgene Corporation
Smart & Biggar
LandOfFree
Biomarkers for monitoring the treatment by quinazolinone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for monitoring the treatment by quinazolinone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for monitoring the treatment by quinazolinone... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1867932